Rapid Reactions: Expanding Treatment Options in Relapsed/Refractory Multiple Myeloma
Key Points
-
SUCCESSOR-2 met its primary end point, with mezigdomide plus carfilzomib and dexamethasone demonstrating a median progression-free survival of 18 months compared with 8.3 months for carfilzomib and dexamethasone alone (HR, 0.48).
-
Mezigdomide, a novel cereblon E3 ligase modulator, produced durable activity across multiple high-risk patient populations, including those with extramedullary disease, high-risk cytogenetics, prior B-cell maturation antigen-directed therapy exposure, and refractory disease.
-
The safety profile was predictable and manageable, with neutropenia representing the most common adverse event and generally responding well to proactive growth factor support, while serious opportunistic infections remained uncommon.
-
Investigators highlighted mezigdomide’s potential role across the treatment continuum, noting that its strong efficacy, oral administration, and immune-activating properties may make it a valuable option alongside CAR T-cell therapies and bispecific antibodies in relapsed/refractory multiple myeloma.
Coinciding with the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Rahul Gosain, MD, MBA, of Wilmot Cancer Institute, and co-host of the Oncology Brothers podcast, spoke with Paul Richardson, MD, of Dana-Farber Cancer Institute, about the phase 3 SUCCESSOR-2 trial evaluating mezigdomide in patients with relapsed/refractory multiple myeloma (RRMM). The discussion focused on the drug’s unique mechanism of action, clinical efficacy, safety profile, and its potential role in an increasingly complex treatment landscape.
Mezigdomide belongs to a class of agents known as cereblon E3 ligase modulators (CELMoDs), which are designed to enhance degradation of key transcription factors involved in myeloma cell survival. The agent acts as a highly potent cereblon modulator, resulting in degradation of Ikaros and Aiolos while simultaneously stimulating immune activity, Dr. Richardson said. This dual mechanism contributes to both direct antimyeloma effects and immune-mediated tumor control, leading Dr. Richardson to describe the therapy as an immune-activating treatment that can be used across a broad spectrum of relapsed disease settings.
From Early-Phase Activity to Phase 3 Success: The Development of Mezigdomide
Early clinical development provided encouraging evidence of activity in heavily pretreated populations. Phase 1 studies established a recommended dose of 1 mg once daily administered on a 3-weeks-on, 1-week-off schedule. In patients with highly refractory disease, including those previously exposed to BCMA-directed therapies, mezigdomide monotherapy produced an overall response rate of approximately 41%. Activity was also observed in patients with extramedullary disease, a population that historically has had limited treatment options. Subsequent combination studies further demonstrated substantial synergy with multiple established myeloma agents, including carfilzomib, daratumumab, and elotuzumab.
These findings provided the foundation for the phase 3 SUCCESSOR-2 study, which compared mezigdomide plus carfilzomib and dexamethasone with carfilzomib and dexamethasone alone. The global trial incorporated an initial dose-optimization phase before the primary efficacy confirmation. Dr. Richardson emphasized that the trial’s broad geographic representation ensures the results apply seamlessly to diverse patient populations and everyday clinical practice.
SUCCESSOR-2 met its primary end point, demonstrating a median progression-free survival (PFS) of 18 months with the mezigdomide-based triplet compared with 8.3 months for carfilzomib and dexamethasone alone. The resulting hazard ratio of 0.48 reflected a substantial reduction in the risk of disease progression or death. Furthermore, PFS2 analyses were also favorable, suggesting that earlier use of mezigdomide did not compromise future treatment opportunities and continued to provide benefit beyond initial disease control.
Manageable Safety and Consistent Efficacy Across High-Risk Subgroups
Although overall survival data remain immature, early trends favored the mezigdomide-containing regimen. Dr. Richardson highlighted the absence of treatment crossover in the study, noting that this may ultimately provide a clearer assessment of long-term survival outcomes than has been observed in some prior studies evaluating novel myeloma therapies.
The safety profile observed in SUCCESSOR-2 was generally predictable and manageable. Neutropenia emerged as the primary adverse event associated with mezigdomide, but Dr. Richardson stressed that this toxicity can be effectively addressed through proactive use of growth factor support. He noted that the neutropenia appears to be related to cellular differentiation rather than stem cell injury, making it both expected and manageable in clinical practice.
Importantly, investigators did not identify unexpected toxicities or significant increases in opportunistic infections. Rates of intravenous immunoglobulin use remained relatively low, and serious infectious complications were uncommon. Dr. Richardson recommended routine consideration of Pneumocystis jirovecii pneumonia prophylaxis and emphasized the importance of thromboprophylaxis, given the low but notable incidence of thromboembolic events observed during development. Overall, he characterized the treatment as straightforward to administer and particularly well suited for both academic and community oncology settings.
One of the most notable findings from SUCCESSOR-2 was the consistency of benefit across patient subgroups. The improvement in outcomes was maintained among patients with high-risk cytogenetics, extramedullary disease, prior BCMA-directed therapy exposure, and refractory disease. Hazard ratios remained favorable across multiple analyses, reinforcing confidence that the therapeutic effect extends to patient populations that often experience poorer outcomes with existing therapies, Dr. Richardson said.
Integrating Mezigdomide Into Modern Multiple Myeloma Care
The discussion also addressed how mezigdomide may fit alongside cellular therapies and bispecific antibodies. As treatment options continue to expand in RRMM, Dr. Richardson suggested that mezigdomide provides physicians with an additional highly active therapy that can be incorporated without limiting future treatment strategies. Because the agent appears to preserve immune function while maintaining robust antimyeloma activity, it may serve as an important bridge or alternative for patients who are not immediate candidates for chimeric antigen receptor T-cell therapy or other advanced immunotherapies.
With the positive results from SUCCESSOR-2, mezigdomide appears poised to become an important addition to the treatment armamentarium for RRMM. The combination of meaningful efficacy, manageable toxicity, oral administration, and broad activity across high-risk populations positions the therapy as a potentially valuable option for patients and clinicians seeking effective treatments beyond currently available standards of care.